問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳怡豪
下載
2021-12-01 - 2026-11-30
Condition/Disease
Test Drug
Participate Sites6Sites
Recruiting6Sites
2019-12-01 - 2024-12-31
Participate Sites7Sites
Recruiting7Sites
2020-07-22 - 2025-11-30
2025-06-01 - 2026-12-31
Participate Sites9Sites
Recruiting9Sites
2021-08-15 - 2026-05-31
Participate Sites8Sites
Recruiting8Sites
2022-06-01 - 2027-07-30
2025-01-01 - 2030-02-01
Participate Sites5Sites
Recruiting5Sites
2020-12-01 - 2023-12-31
Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Futibatinib（TAS-120）
全部
